Evidence map›Paper›PMID 40191610›Full record

ArticleFrontiers in genetics2025

Cancer classification in high dimensional microarray gene expressions by feature selection using eagle prey optimization.

Swetha Dhamercherla, Damodar Reddy Edla, Suresh Dara

Abstract read
In one paragraph

Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Swetha DhamercherlaDepartment of Computer Science and Engineering, National Institute of Technology, Farmagudi, Goa, India.
Damodar Reddy EdlaDepartment of Computer Science and Engineering, National Institute of Technology, Farmagudi, Goa, India.
Suresh DaraSchool of Computer Science and Engineering, VIT-AP University, Amaravati, Andhra Pradesh, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Microarray gene expression data have emerged as powerful tools in cancer classification and diagnosis. However, the high dimensionality of these datasets presents significant challenges for feature selection, leading to the development of various computational methods. In this paper, we utilized the Eagle Prey Optimization (EPO), a novel genetically inspired approach for microarray gene selection in cancer classification. EPO draws inspiration from the remarkable hunting strategies of eagles, which exhibit unparalleled precision and efficiency in capturing prey. Similarly, our algorithm aims to identify a small subset of informative genes that can discriminate between cancer subtypes with high accuracy and minimal redundancy. To achieve this, EPO employs a combination of genetic mutation operator with EPO fitness function, to evolve a population of potential gene subsets over multiple generations. The key innovation of EPO lies in its incorporation of a fitness function specifically designed for cancer classification tasks. This function considers not only the discriminative power of selected genes but also their diversity and redundancy, ensuring the creation of compact and informative gene subsets. Moreover, EPO incorporates a mechanism for adaptive mutation rates, allowing the algorithm to explore the search space efficiently. To validate the effectiveness of EPO, extensive experiments were conducted on several publicly available microarray datasets representing different cancer types. Comparative analysis with state-of-the-art gene selection algorithms demonstrates that EPO consistently outperforms these methods in terms of classification accuracy, dimensionality reduction, and robustness to noise.

Indexed as

cancer classificationfeature optimizationfeature selectionmeta-heuristic optimizationmicroarray gene selection

Identifiers

PMID40191610
PMCPMC11968723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.